A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.
作者信息
Jiang Chao, Mei Miao, Li Bin, Zhu Xiurui, Zu Wenhong, Tian Yujie, Wang Qiannan, Guo Yong, Dong Yizhou, Tan Xu
机构信息
School of Pharmaceutical Sciences, Center for Infectious Disease Research, School of Medicine, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
出版信息
Cell Res. 2017 Mar;27(3):440-443. doi: 10.1038/cr.2017.16. Epub 2017 Jan 24.
Abstract
摘要
相似文献
1
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.一种用于在体内治疗性靶向乙肝病毒（HBV）DNA和前蛋白转化酶枯草溶菌素9（pcsk9）的非病毒CRISPR/Cas9递送系统。
Cell Res. 2017 Mar;27(3):440-443. doi: 10.1038/cr.2017.16. Epub 2017 Jan 24.
2
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.PCSK9（前蛋白转化酶枯草杆菌蛋白酶/克新9型）的体内碱基编辑作为基因组编辑的一种治疗替代方法。
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub 2017 Jul 27.
3
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.CRISPR/Cas9系统通过靶向乙肝病毒基因组的保守区域来抑制乙肝病毒。
J Gen Virol. 2015 Aug;96(8):2252-2261. doi: 10.1099/vir.0.000159. Epub 2015 Apr 22.
4
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.利用细菌CRISPR/Cas RNA引导的DNA内切酶抑制慢性感染细胞中乙型肝炎病毒DNA的积累
Virology. 2015 Feb;476:196-205. doi: 10.1016/j.virol.2014.12.001. Epub 2014 Dec 29.
5
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.体内对人肝细胞中前蛋白转化酶枯草溶菌素9进行CRISPR-Cas9靶向作用——简要报告
Arterioscler Thromb Vasc Biol. 2016 May;36(5):783-6. doi: 10.1161/ATVBAHA.116.307227. Epub 2016 Mar 3.
6
CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.阳离子三嵌段共聚物纳米粒通过 CES1 触发肝脏特异性货物释放 CRISPR/Cas9 元件，靶向 PCSK9 基因编辑改善高血脂症
Adv Sci (Weinh). 2023 Jul;10(19):e2300502. doi: 10.1002/advs.202300502. Epub 2023 Apr 21.
7
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.CRISPR/Cas9在肝癌细胞和转基因小鼠中产生抗乙肝病毒的作用。
Virus Res. 2016 Jun 2;217:125-32. doi: 10.1016/j.virusres.2016.04.003. Epub 2016 Apr 2.
8
CRISPR/Cas9 Gene Targeting in Primary Mouse Bone Marrow-Derived Macrophages.CRISPR/Cas9 基因靶向敲除原发性小鼠骨髓来源巨噬细胞。
Methods Mol Biol. 2020;2097:223-230. doi: 10.1007/978-1-0716-0203-4_14.
9
An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles.关于在单细胞期小鼠胚胎中使用CRISPR/Cas9技术生成复杂突变等位基因的最新进展。
Cell Death Differ. 2017 Oct;24(10):1821-1822. doi: 10.1038/cdd.2017.122. Epub 2017 Jul 28.
10
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?以前蛋白转化酶枯草溶菌素9（PCSK9）为靶点以获得治疗益处：我们是否已解决所有问题？
Atherosclerosis. 2016 May;248:62-75. doi: 10.1016/j.atherosclerosis.2016.02.018. Epub 2016 Mar 9.
引用本文的文献
1
Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products.针对cccDNA的治疗干预措施：揭示作用机制并评估天然产物的效力
Front Cell Infect Microbiol. 2025 Jun 17;15:1598872. doi: 10.3389/fcimb.2025.1598872. eCollection 2025.
2
Dual SORT LNPs for multi-organ base editing.用于多器官碱基编辑的双SORT脂质纳米颗粒
Nat Biotechnol. 2025 Jun 2. doi: 10.1038/s41587-025-02675-z.
3
Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice.新生小鼠静脉注射脂质体CRISPR/Cas9复合物后未出现脱靶或肿瘤情况。
Pharmaceutics. 2025 May 17;17(5):656. doi: 10.3390/pharmaceutics17050656.
4
Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection.非酒精性脂肪性肝病中的治疗性纳米材料：在合并乙型肝炎病毒感染患者中的当前进展及潜在应用
Int J Nanomedicine. 2025 Mar 25;20:3803-3823. doi: 10.2147/IJN.S510271. eCollection 2025.
5
Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B.靶向乙肝cccDNA水平：实现慢性乙型肝炎完全治愈的关键
Pathogens. 2024 Dec 13;13(12):1100. doi: 10.3390/pathogens13121100.
6
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles.工程化 Cas9 酶通过脂质纳米粒在小鼠肝脏中实现治疗性基因组编辑。
Nat Commun. 2024 Nov 7;15(1):9173. doi: 10.1038/s41467-024-53418-8.
7
The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption.乙肝治愈的潜力：CRISPR介导的乙肝病毒基因破坏概述
Front Genome Ed. 2024 Oct 9;6:1467449. doi: 10.3389/fgeed.2024.1467449. eCollection 2024.
8
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.用于家族性高胆固醇血症的已确立和新兴核酸疗法。
Circulation. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.
9
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders.用于肝脏疾病的脂质纳米颗粒核酸疗法。
Acta Pharm Sin B. 2024 Jul;14(7):2885-2900. doi: 10.1016/j.apsb.2024.04.015. Epub 2024 Apr 22.
10
An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo.一种抗污膜融合脂质体，用于体内有效的细胞内递药。
Nat Commun. 2024 May 20;15(1):4267. doi: 10.1038/s41467-024-46533-z.
本文引用的文献
1
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.通过在体内联合病毒和非病毒递送CRISPR系统组件进行治疗性基因组编辑。
Nat Biotechnol. 2016 Mar;34(3):328-33. doi: 10.1038/nbt.3471. Epub 2016 Feb 1.
2
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.前蛋白转化酶枯草溶菌素9抑制剂与心血管疾病：开启新的治疗时代
Curr Opin Lipidol. 2015 Dec;26(6):511-20. doi: 10.1097/MOL.0000000000000239.
3
Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.CRISPR 系统的生物学与应用：利用大自然的工具箱进行基因组工程。
Cell. 2016 Jan 14;164(1-2):29-44. doi: 10.1016/j.cell.2015.12.035.
4
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.用于体内mRNA递送的类脂质纳米颗粒的正交阵列优化
Nano Lett. 2015 Dec 9;15(12):8099-107. doi: 10.1021/acs.nanolett.5b03528. Epub 2015 Nov 6.
5
Targeting hepatitis B virus cccDNA using CRISPR/Cas9.利用 CRISPR/Cas9 靶向乙型肝炎病毒共价闭合环状 DNA。
Antiviral Res. 2015 Nov;123:188-92. doi: 10.1016/j.antiviral.2015.10.004. Epub 2015 Oct 22.
6
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.HBV cccDNA：病毒持续感染的储存库，也是慢性乙型肝炎治愈的关键障碍。
Gut. 2015 Dec;64(12):1972-84. doi: 10.1136/gutjnl-2015-309809. Epub 2015 Jun 5.
7
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.CRISPR/Cas9对病毒DNA的切割能有效抑制乙型肝炎病毒。
Sci Rep. 2015 Jun 2;5:10833. doi: 10.1038/srep10833.
8
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.CRISPR/Cas9系统通过靶向乙肝病毒基因组的保守区域来抑制乙肝病毒。
J Gen Virol. 2015 Aug;96(8):2252-2261. doi: 10.1099/vir.0.000159. Epub 2015 Apr 22.
9
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.利用 CRISPR/Cas9 核酸酶靶向乙型肝炎病毒 cccDNA 可有效抑制病毒复制。
Antiviral Res. 2015 Jun;118:110-7. doi: 10.1016/j.antiviral.2015.03.015. Epub 2015 Apr 3.
10
In vivo genome editing using Staphylococcus aureus Cas9.使用金黄色葡萄球菌Cas9进行体内基因组编辑。
Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1.
Zotero 插件